A carregar...

Systematic review of dasatinib in chronic myeloid leukemia

Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Breccia, Massimo, Salaroli, Adriano, Molica, Matteo, Alimena, Giuliana
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3615898/
https://ncbi.nlm.nih.gov/pubmed/23569389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S35360
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!